Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.62 and traded as high as $0.7176. Galmed Pharmaceuticals shares last traded at $0.6775, with a volume of 115,859 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Galmed Pharmaceuticals Stock Up 9.3%

The firm’s 50 day simple moving average is $0.62 and its 200 day simple moving average is $0.74. The company has a market cap of $3.71 million, a price-to-earnings ratio of -0.55 and a beta of 0.62.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.